Back to top

gene-editing: Archive

Zacks Equity Research

Century (IPSC) Up 36% on FDA Nod to Begin Phase I Lupus Study

Century (IPSC) set to begin early-stage study on lead product candidate, CNTY-101, for treatment of systemic lupus erythematosus following IND clearance by FDA. The stock rises 36%.

AGENPositive Net Change PBYIPositive Net Change ADMAPositive Net Change IPSCPositive Net Change